Targeting death-inducing receptors in cancer therapy (Q36832154)

16 August 2017

1 reference

title

Targeting death-inducing receptors in cancer therapy (English)

1 reference

16 August 2017

5

Smyth MJ

1 reference

16 August 2017

Takeda K

1

1 reference

16 August 2017

Stagg J

series ordinal

2

1 reference

16 August 2017

Yagita H

series ordinal

3

1 reference

16 August 2017

Okumura K

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

16 August 2017

1 reference

16 August 2017

26

1 reference

16 August 2017

3745-3757

1 reference

16 August 2017

25

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1210374

16 August 2017

0 references

cites work

Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile vaccination against tumors by dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Death receptors: signaling and modulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Safety and antitumor activity of recombinant soluble Apo2 ligand

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Monoclonal antibodies targeting the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Fc receptors are required in passive and active immunity to melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Signaling antibodies in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

A phase I clinical trial of recombinant human tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Costimulation of T cells by OX40, 4-1BB, and CD27.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Cell death: critical control points

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Expression of TRAIL and TRAIL receptors in normal and malignant tissues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Therapeutics targeting signal transduction for patients with colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

TRAIL-R as a negative regulator of innate immune cell responses.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

The immunobiology of cancer immunosurveillance and immunoediting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

CTLA-4: new insights into its biological function and use in tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Complement function in mAb-mediated cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Monoclonal antibodies as effective therapeutic agents for solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Apoptosis: a link between cancer genetics and chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

On the TRAIL of a new therapy for leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Targeting death receptors in cancer with Apo2L/TRAIL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Apo2L/TRAIL and its death and decoy receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Involvement of TRAIL and its receptors in viral hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

From bench to clinic with apoptosis-based therapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Targeting death receptors in bladder, prostate and renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Lethal effect of the anti-Fas antibody in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Cancer immunotherapy: breaking the barriers to harvest the crop

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Tumour-educated macrophages promote tumour progression and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Modulating the immune response with dendritic cells and their growth factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Avoiding premature apoptosis of normal epidermal cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Immune complex-mediated antigen presentation induces tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Regulation of death receptor-mediated apoptosis pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Nature's TRAIL--on a path to cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Mechanisms and genes of cellular suicide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

A novel domain within the 55 kd TNF receptor signals cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Apoptosis in the pathogenesis and treatment of disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Fas receptor-mediated apoptosis: a clinical application?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Eradication of established tumors in mice by a combination antibody-based therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Interferon-γ Sensitizes Human Myeloid Leukemia Cells to Death Receptor-mediated Apoptosis by a Pleiotropic Mechanism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

The pathophysiology of tumor necrosis factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Tumor necrosis factor receptor and Fas signaling mechanisms.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

TNF/TNFR family members in costimulation of T cell responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

TRAIL and its receptors as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210374

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210374

1 reference

Dimensions Publication ID

16 August 2017

0 references

1 reference